Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a buy rating to a hold rating in a report published on Friday.

A number of other analysts have also recently commented on the stock. Craig Hallum lowered their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. JMP Securities dropped their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $8.60.

Ironwood Pharmaceuticals Stock Performance

IRWD opened at $1.41 on Friday. The company has a fifty day moving average price of $2.27 and a two-hundred day moving average price of $3.48. The firm has a market capitalization of $225.64 million, a PE ratio of -47.00 and a beta of 0.37. Ironwood Pharmaceuticals has a 52 week low of $1.34 and a 52 week high of $9.01.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). The firm had revenue of $90.55 million during the quarter, compared to analyst estimates of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. Equities analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the sale, the chief executive officer now owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Michael Shetzline sold 41,269 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the transaction, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 192,381 shares of company stock valued at $338,591 in the last 90 days. 12.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRWD. KBC Group NV grew its position in shares of Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,198 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $36,000. Journey Strategic Wealth LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at approximately $45,000. Catalyst Funds Management Pty Ltd acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $47,000. Finally, Xponance Inc. acquired a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter valued at $50,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.